관류 영상 진단 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the perfusion radiology market size is expected to increase from USD 3.03 billion in 2025 to USD 3.20 billion in 2026 and reach USD 4.24 billion by 2031, growing at a CAGR of 5.80% over 2026-2031.

This report is Segmented by Modality (CT Perfusion, MRI Perfusion, and More), Application (Neurology, Cardiology, Oncology, and More), End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Perfusion Radiology Market Trends and Insights

Rising Stroke Incidence Creates Irreversible Demand for Time-Sensitive Perfusion Tools

Stroke remains the primary driver of demand in the perfusion radiology market, as timely treatment depends on quickly identifying salvageable tissue versus irreversible damage. The 2025 Global Stroke Fact Sheet estimated the annual global cost of strokes at over USD 890 billion, highlighting the need for faster triage tools and standardized imaging protocols. A 2024 forecast from the Journal of the American Heart Association projected global stroke cases to reach 21.43 million by 2050, indicating sustained demand for perfusion evaluations. Comprehensive stroke centers increasingly use real-time CT Perfusion maps to guide thrombectomy decisions, especially for patients presenting beyond the optimal treatment window. In 2024 and 2025, Chinese hospitals adopted 60-second whole-brain CT perfusion with head-to-neck CTA, expanding its use from flagship centers to broader hospital networks under guideline-driven triage models. This trend reflects the market's focus on addressing rising patient volumes and ensuring consistent acute stroke decision-making across healthcare systems.

AI-Enabled Quantitative Perfusion Analysis Redefines Platform Competition

Quantitative software has become a key competitive factor in the perfusion radiology market, with buyers demanding speed, consistency, and clinically relevant outputs from a single platform. Stroke centers in North America and Europe now expect automated perfusion maps, ischemic core segmentation, and care-team alerts as standard workflow features. A 1,591-case study presented at ESOC 2025 showed RapidAI detected 93% of medium vessel occlusions with CT perfusion imaging, outperforming a competing platform's 70% detection rate.] Research is advancing toward contrast-free methods, with a 2026 study demonstrating that a generative AI model produced competitive perfusion maps using non-contrast CT data. If validated at scale, this approach could reduce reliance on contrast administration, addressing a key access barrier in the market. FDA clearance pathways remain critical in determining how quickly these innovations transition from research to clinical use.

Contrast Agent Safety and Renal Risk Create Sustained Clinical Friction

Contrast administration remains a significant challenge in the perfusion radiology market, as many patients requiring urgent perfusion imaging also face renal risks or have a history of adverse reactions. CT Perfusion relies on iodinated contrast, while MRI perfusion raises concerns about gadolinium exposure, ensuring both methods undergo intense clinical scrutiny. This scrutiny, particularly for elderly patients and those with chronic kidney disease, slows adoption despite the acknowledged diagnostic value of perfusion imaging. Additionally, software supporting automated dosing recommendations faces stricter regulatory scrutiny. Although research into contrast-free methods is advancing, with non-contrast CT showing promise through generative AI models, contrast-related challenges will persist in the near term due to the time required for validation, workflow adjustments, and building clinical trust.

Other drivers and restraints analyzed in the detailed report include:

1. Imaging Department Automation Addresses Radiologist Capacity Constraints
2. Oncology Perfusion Expands the Addressable Clinical Base
3. Workflow Fragmentation Limits Scalable Deployment Across Multi-Site Networks

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, CT Perfusion held a 42.45% share, maintaining its leadership in the perfusion radiology market. Its dominance is driven by speed, widespread scanner availability, and seamless integration into emergency stroke workflows, where timely imaging significantly impacts treatment decisions. Hospitals' adoption of 60-second whole-brain acquisition on advanced 512-slice systems further strengthened this position, enabling simultaneous scanning with CTA for acute cerebrovascular cases. Nuclear medicine perfusion remains critical in cardiology and oncology, offering quantitative flow assessments that surpass anatomical evaluations. Doppler and echocardiography-based perfusion continue to be relevant in cost-sensitive cardiac settings and community care environments lacking CT or MRI infrastructure.

MRI Perfusion is projected to grow at a 7.25% CAGR through 2031, making it the fastest-growing modality in the perfusion radiology market. Its advantages include radiation-free imaging and superior soft-tissue characterization, making it essential for oncology follow-ups, pediatric cases, and long-term neurological evaluations. Research at Erlangen is advancing the integration of perfusion measurements and image fusion into multiparametric brain tumor MRIs, enhancing therapy monitoring and differential diagnosis. In 2025, Philips demonstrated that automating scan planning and perfusion quantification within a unified workflow simplifies cardiac MRI scaling. This trend indicates a shift toward routine MRI adoption beyond specialized centers.

Complete Report Scope:

• By Modality
  • CT Perfusion
  • MRI Perfusion
  • Nuclear Medicine Perfusion
  • Doppler and Echocardiography-Based Perfusion
• By Application
  • Neurology
  • Cardiology
  • Oncology
  • Pulmonology
  • Transplantation
  • Emergency Medicine
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America held a dominant 40.25% share of the perfusion radiology market, with the U.S. leading due to advanced stroke centers, AI-driven imaging software, and strong payment support for nuclear and cardiac perfusion. Enhanced reimbursement for radiopharmaceuticals and PET imaging encourages providers to expand capacity and adopt complex workflows. Policy clarity accelerates the transition from equipment purchase to routine use, linking capital investments to clearer revenue models. Europe, particularly Germany, the U.K., and France, serves as a key clinical validation hub, with academic centers standardizing newer perfusion methods.

Asia-Pacific is projected to grow at an 8.12% CAGR through 2031, making it the fastest-growing region in the perfusion radiology market. Countries like China, India, Japan, South Korea, and Australia are driving growth through a combination of disease burdens, hospital investments, and digital healthcare adoption. In China, hospitals are integrating AI-driven perfusion post-processing alongside scanner expansions, streamlining stroke diagnoses and improving workflow consistency. This trend reflects a maturing market in Asia-Pacific, with advancements in workflow sophistication and hardware depth supporting long-term adoption.

The Middle East, Africa, South America, and parts of Asia-Pacific exhibit clear demand for perfusion radiology despite smaller revenue contributions. GCC countries are integrating premium imaging infrastructure into tertiary hospitals, advancing cardiac PET and CT perfusion. Brazil and South Africa act as regional leaders with more developed diagnostic imaging networks. However, challenges like reimbursement fragmentation, high import costs, and low radiologist density hinder broader adoption. These constraints create opportunities for cloud-based and subscription models, reducing on-site expenses and catering to less dense clinical networks.

1. Bayer
2. Bracco Imaging S.p.A.
3. Canon
4. Cercare Medical A/S
5. FUJIFILM
6. GE HealthCare Technologies Inc.
7. Guerbet S.A.
8. HeartFlow, Inc.
9. Koninklijke Philips
10. Lantheus Holdings, Inc.
11. Olea Medical S.A.
12. Profound Medical
13. RadNet, Inc.
14. Ram Soft
15. RapidAI, Inc.
16. Shimadzu
17. Siemens Healthineers
18. TeraRecon, Inc.
19. United Imaging Healthcare Co., Ltd.
20. Viz.ai, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Stroke and Acute Coronary Workflow Dependence on Rapid Perfusion Decisions
  • 4.2.2 Expansion of AI-Enabled Quantitative Perfusion Analysis in Radiology Workflows
  • 4.2.3 Imaging Department Productivity Pressure, Driving Automated Reconstruction and Interpretation
  • 4.2.4 Growing Adoption of CT Perfusion in Emergency and Neurovascular Care Pathways
  • 4.2.5 Increasing Use of Advanced Perfusion Analytics for Oncology, Cardiology, and Transplant Evaluation
  • 4.2.6 Reimbursement Support for Advanced Cardiac and Neuro Imaging Analytics
• 4.3 Market Restraints
  • 4.3.1 Contrast Agent Safety, Renal Risk, and Operational Screening Burden
  • 4.3.2 Workflow Fragmentation Across PACS, RIS, and Vendor-Specific Perfusion Software
  • 4.3.3 High Capital and Subscription Cost of Advanced Perfusion Platforms
  • 4.3.4 Limited Access to Trained Radiologists and Technologists in Smaller and Emerging Healthcare Facilities
• 4.4 Value/ Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Modality
  • 5.1.1 CT Perfusion
  • 5.1.2 MRI Perfusion
  • 5.1.3 Nuclear Medicine Perfusion
  • 5.1.4 Doppler and Echocardiography-Based Perfusion
• 5.2 By Application
  • 5.2.1 Neurology
  • 5.2.2 Cardiology
  • 5.2.3 Oncology
  • 5.2.4 Pulmonology
  • 5.2.5 Transplantation
  • 5.2.6 Emergency Medicine
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Diagnostic Imaging Centers
  • 5.3.3 Ambulatory Surgical Centers
  • 5.3.4 Academic and Research Institutes
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Bayer AG
  • 6.3.2 Bracco Imaging S.p.A.
  • 6.3.3 Canon Medical Systems Corporation
  • 6.3.4 Cercare Medical A/S
  • 6.3.5 FUJIFILM Holdings Corporation
  • 6.3.6 GE HealthCare Technologies Inc.
  • 6.3.7 Guerbet S.A.
  • 6.3.8 HeartFlow, Inc.
  • 6.3.9 Koninklijke Philips N.V.
  • 6.3.10 Lantheus Holdings, Inc.
  • 6.3.11 Olea Medical S.A.
  • 6.3.12 Profound Medical Corp.
  • 6.3.13 RadNet, Inc.
  • 6.3.14 RamSoft, Inc.
  • 6.3.15 RapidAI, Inc.
  • 6.3.16 Shimadzu Corporation
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 TeraRecon, Inc.
  • 6.3.19 United Imaging Healthcare Co., Ltd.
  • 6.3.20 Viz.ai, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment